Experimental drug targets rare blood disorder in phase 3 trial
NCT ID NCT03205995
First seen Jan 02, 2026 · Last updated May 25, 2026 · Updated 16 times
Summary
This study tested a drug called narsoplimab (OMS721) in adults and teenagers with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The main goal was to see if the drug could improve platelet counts and was safe. The trial was stopped early after enrolling only 6 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Omeros Investigational Site
Chicago, Illinois, 60643, United States
-
Omeros Investigational Site
Vilnius, Lithuania
-
Omeros Investigational Site
Lodz, Poland
-
Omeros Investigational Site
New Taipei City, Taiwan
Conditions
Explore the condition pages connected to this study.